Literature DB >> 27289575

[Risk factors of lung cancer complicated with symptomatic venous thromboembolism].

C Y Gong1, Z W Li, D X Zhou, H Yan, J Bao, R J Ye, Z L Cao, Z C Gao, X L Mu.   

Abstract

OBJECTIVE: To seek risk factors of VTE in patients with lung cancer through analysis of clinical features of patients with lung cancer complicated with venous thromboembolism (VTE).
METHODS: Retrospective investigation was performed on patients diagnosed with lung cancer and with complete clinical data who were hospitalized in Peking University People's Hospital from January 1, 2010 to December 31, 2014. According to the presence of symptomatic VTE, patients were distributed into two groups, VTE group and control group. Patients' clinical data and laboratory parameters were collected. Single factor analysis was applied to compare the differences between the two groups. t test or nonparametric test was applied for intragroup comparison of measurement data, and chi-square test was applied for the comparison of counting information. Logistic regression analysis was applied to explore risk factors of venous thromboembolism. For VTE patients with this diagnosis when they were hospitalized, D-dimer and PT were obtained after the occurrence of VTE, so D-dimer and PT were eliminated in the multiple factors analysis. SPSS 13.0 statistical software was applied for statistical management and analysis.
RESULTS: 548 patients with lung cancer were include in the investigation, with male 357, female 191, average age of (63.8±10.9) years old, 46 patients in VTE group and 502 patinets in control group. According to the results of single factor analysis in gender, age, tumor pathologic type, tumor stage, WBC, Hb, PLT, CEA, ALT, FIB, D-dimer, PT, APTT, PT-INR, the tumor stage (χ(2)=14.177), CEA (t=2.129) and Hb (t=-2.424) were risk factors for lung cancer patients complicated with venous thromboembolism. Logistic regression analysis showed that tumor stage was the independent risk factor of lung cancer complicated with venous thromboembolism (OR 2.058, 95%CI 1.307-3.238, P=0.002) , and CEA (r=0.395, P<0.001) and Hb (r=-0.144, P=0.001) were associated with lung cancer stage. The area under the curve formed by D-dimer predicting VTE was 0.825 (95%CI 0.751-0.900, P<0.001).
CONCLUSION: Tumor stage is the only risk factor for lung cancer patients complicated with venous thromboembolism in the study. However, because this study is a retrospective study, other potential high risk factors causing VTE cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27289575     DOI: 10.3760/cma.j.issn.1001-0939.2016.06.010

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  4 in total

1.  Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.

Authors:  Jiqiang Guo; Ying Gao; Zhihua Gong; Pengfei Dong; Yajie Mao; Fang Li; Jianrong Rong; Junping Zhang; Yongnian Zhou; Huijing Feng; Hongxia Guo; Linxia Gu; Meiwen An; Kaixue Wen; Jin Zhang
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

2.  One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis).

Authors:  Nobuyasu Awano; Tetsuya Okano; Riken Kawachi; Masaru Matsumoto; Tetsuya Kimura; Atsushi Takita; Mari S Oba; Hideo Kunitoh
Journal:  JTO Clin Res Rep       Date:  2022-08-08

3.  Incidence of venous thromboembolism after surgery for adenocarcinoma in situ and the validity of the modified Caprini score: A propensity score-matched study.

Authors:  Yong-Sheng Cai; Hong-Hong Dong; Xin-Yang Li; Xin Ye; Shuo Chen; Bin Hu; Hui Li; Jin-Bai Miao; Qi-Rui Chen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

4.  [Risk Factors Associated with Venous Thromboembolism after Lung Cancer Surgery: A Single-center Study].

Authors:  Songping Cui; Hui Li; Bo Tian; Chunfeng Song; Bin Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.